| 8.85 8.85 (0.11%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.68  |
1-year : | 12.47 |
| Resists | First : | 9.14 |
Second : | 10.68 |
| Pivot price | 8.16 |
|||
| Supports | First : | 7.42 |
Second : | 6.36 |
| MAs | MA(5) : | 8.69 |
MA(20) : | 7.84 |
| MA(100) : | 7.27 |
MA(250) : | 11.48 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 90.6 |
D(3) : | 89.7 |
| RSI | RSI(14): 68.4 |
|||
| 52-week | High : | 24.17 | Low : | 5.84 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ARCT ] has closed below upper band by 22.2%. Bollinger Bands are 35.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.16 - 9.19 | 9.19 - 9.22 |
| Low: | 8.73 - 8.77 | 8.77 - 8.81 |
| Close: | 8.79 - 8.85 | 8.85 - 8.9 |
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
Tue, 14 Apr 2026
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Fri, 06 Mar 2026
Arcturus Therapeutics: Downgrading to 'Hold' As CF Program Shifts Population Focus (ARCT) - Seeking Alpha
Tue, 03 Mar 2026
Arcturus Therapeutics (ARCT) trims 2025 loss and extends cash runway into Q2 2028 - Stock Titan
Mon, 16 Feb 2026
Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Mon, 09 Feb 2026
Citi lowers price target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, maintains neutral rating - MSN
Mon, 02 Feb 2026
Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 28 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 7.5 (%) |
| Held by Institutions | 78.5 (%) |
| Shares Short | 5,940 (K) |
| Shares Short P.Month | 6,570 (K) |
| EPS | -2.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.53 |
| Profit Margin | -80.2 % |
| Operating Margin | -435.1 % |
| Return on Assets (ttm) | -15.5 % |
| Return on Equity (ttm) | -29 % |
| Qtrly Rev. Growth | -68.5 % |
| Gross Profit (p.s.) | -1.07 |
| Sales Per Share | 2.88 |
| EBITDA (p.s.) | -2.58 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -74 (M) |
| Levered Free Cash Flow | 9 (M) |
| PE Ratio | -3.69 |
| PEG Ratio | 0 |
| Price to Book value | 1.17 |
| Price to Sales | 3.06 |
| Price to Cash Flow | -3.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|